AN2 Therapeutics, Inc. (ANTX) News
Follow AN2 Therapeutics, Inc. (ANTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
AN2 Therapeutics Q3 Loss Narrows on Lower Expenses
EQUITY | Nov 09, 2026, 12:38 PM UTC
M
AN2 Therapeutics Reports Third-Quarter Loss of $7.96 Million
EQUITY | Nov 09, 2026, 12:33 PM UTC
M
AN2 Therapeutics Reports Third-Quarter 2026 Financial Results
AN2 Therapeutics reported financial results for the quarter ended September 30, 2026; the supplied text provides no financial figures.
EQUITY | Nov 09, 2026, 12:30 PM UTC
L
AN2 Therapeutics (ANTX) Gets Gates Funding Extension for TB Program
AN2 Therapeutics said the Gates Foundation extended funding to support its ongoing TB research collaboration with GSK on boron-based LeuRS inhibitors.Material DetailsContext by AI AnalystThis is an early-stage R&D fundin
NEWS | Sep 28, 2026, 11:01 AM UTC
L
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Ga
NEWS | Sep 28, 2026, 11:00 AM UTC
L
ANTX - AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
ANTX - AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
NEWS | Sep 16, 2026, 09:34 PM UTC
L
AN2 Therapeutics presents SOHO 2026 data on epetraborole for polycythemia vera
AN2 Therapeutics presented clinical and translational data supporting epetraborole development for polycythemia vera at the SOHO 2026 annual meeting.
EQUITY | Aug 31, 2026, 10:00 PM UTC
L
AN2 Therapeutics Q2 EPS $(0.18) Beats $(0.27) Estimate
AN2 Therapeutics (NASDAQ: ANTX ) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 14.29 percent increase over losses of $(0.21) per share fro
EARNINGS | Aug 11, 2026, 08:33 PM UTC
L
moves among today's upgrades NBIS +7.3%, LITE +6.0%, AKTX +5.7%, URBN +3.1%, YETI +2.2%, HOG +1.8%, GPN +1.5%, USB +0.6%, NFLX -1.8% moves a
moves among today's upgrades NBIS +7.3%, LITE +6.0%, AKTX +5.7%, URBN +3.1%, YETI +2.2%, HOG +1.8%, GPN +1.5%, USB +0.6%, NFLX -1.8% moves among today's positive initiations NNBR +8.0%, RNTX +3.2%, SLNH +15.5%, ANTX +9.6
EQUITY | Jul 20, 2026, 01:42 PM UTC
L
ANTX Initiated Buy W/$9.00 PT at Guggenheim
ANTX Initiated Buy W/$9.00 PT at Guggenheim
EQUITY | Jul 20, 2026, 11:49 AM UTC
L
ANTX new Buy W/ $9 PT @ GUGG
ANTX new Buy W/ $9 PT @ GUGG
EQUITY | Jul 20, 2026, 11:43 AM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Wednesday's pre-market session, with Pulsenmore and Catheter Precision leading the gainers and Nuwellis and Mobile-health Network leading the losers
EQUITY | Jun 24, 2026, 12:09 PM UTC